Trial · NCT04871204
Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer
NCT04871204, Phase 2, Completed, Fredrik Klevebro
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer. Trials, record NCT04871204. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04871204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer
- NCT number
- NCT04871204
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- Fredrik Klevebro
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- Octreotide Injection
- First posted
- 2021-05-04
- Last updated
- 2024-10-31
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weight change in percent (%) | From baseline before surgery, at 1, 2, 3, and 6 months | Weight loss in percent (%) from baseline weight before surgery, measured at 1, 2, 3, and 6 months after surgery |
| Secondary | Changes in gastrointestinal satiety hormone levels | Baseline, 7 days post-surgery and at 1, 2, 3 and 6 months | Measurement of S-GLP-1, S-PYY, S-Ghrelin and S-GIP (prior to octreotide administration), measured at baseline, 7 days post-surgery and after 1, 2, 3 and 6 months. |
| Secondary | Changes in body composition | Baseline, 1, 2, 3, and 6 months | Body composition measured in percent (%) body fat (continuously) |
| Secondary | Changes in nutritional status - PG-SGA | Baseline, 1, 2, 3, and 6 months | Nutritional status measured with the questionnaire PG-SGA |
| Secondary | Changes in nutritional status - EORTC CAX24 | Baseline, 1, 2, 3, and 6 months | Nutritional status measured with the questionnaire EORTC CAX24 |
| Secondary | Health-related Quality of Life - EORTC QLQ-C30 | Baseline, 1, 2, 3 and 6 months | Health-related Quality of Life (HRQOL) measured using EORTC QLQ-C30 at baseline and at 1, 2, 3 and 6 months after randomization |
| Secondary | Health-related Quality of Life - QLQ-OG25 | Baseline, 1, 2, 3 and 6 months | Health-related Quality of Life (HRQOL) measured using QLQ-OG25 at baseline and at 1, 2, 3 and 6 months after randomization |
| Secondary | Percentage (of subjects) in need of enteral nutrition | Baseline, 1, 2, 3 and 6 months | Percentage (of subjects) in need of enteral nutrition with a jejunostomy feeding catheter or nasogastric tube |
| Secondary | Number and type of Adverse Events | From 7 days post-surgery and at 1, 2, 3 and 6 months (continuously) | Number and type of Adverse Events, including known AEs of Sandostatin LAR depot |
| Secondary | Number of patients completing treatment | From first treatment at 7 days post-surgery to last treatment at 2 months | Number of patients completing treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04871204
GET https://conductscience.org/api/trials/v1/NCT04871204/registered